|
Eric Rose, M.D is an accomplished and recognized medical leader, heart surgeon, researcher, and entrepreneur. Working in both academia and industry, he has grown a premier Department of Surgery at Columbia University and has managed, investigated, and developed numerous complex medical technologies ranging from heart transplantation to novel approaches to Alzheimer's disease and bioterrorism. He has authored or co-authored more than 300 scientific publications and has received more than $25 million in NIH support for his research.
Currently on leave from Columbia, Dr. Rose assumed the role of CEO and Chairman of SIGA Technologies in March, 2007. He also serves as Executive Vice President for Life Sciences at MacAndrews and Forbes, Inc.
Professor Roberts is an internationally recognized expert in medicinal, organic and industrial chemistry. Professor Roberts took his B.Sc. and Ph.D. degrees from Salford University and studied at post-doctoral level in Zurich (with A. S. Dreiding) and Harvard (with R. B. Woodward). His academic career has taken him to the Universities of Salford (1972-80), Exeter (1985-95) and Liverpool (1995-date).
In the period 1980-1986, he was the head of research,
Glaxo, Greenford, UK, and at present he is the
head of the chemistry department at Liverpool
University. Professor Roberts' research interests
span medicinal chemistry, biotransformations
and biomimetic catalysts as well as asymmetric
synthesis. He collaborates with and consults
for pharmaceutical, polymer, paint and biotech
companies and is on the board of three companies,
Ultrafine Chemicals, Charterhouse Therapeutics
(founder) and Stylacat (founder).
Dr. Ann Marie Schmidt is an internationally recognized expert in vascular biology, a field that applies basic research in a range of disciplines to gain insights into disease pathogenesis and to develop new therapeutic approaches for the treatment of arteriosclerosis, diabetes, inflammation, thrombosis, and malignancy. Dr. Schmidt received her M.D. (honors) from New York University School of Medicine.
After training in clinical medicine and hematology / oncology, Dr. Schmidt embarked on her career as a full-time investigator. She is an Associate Professor of Surgical Science and Medicine at the College of Physicians and Surgeons of Columbia University. Dr. Schmidt has presented her work on RAGE at many national and international scientific meetings, including the Gordon Research Conference of Vascular Biology, the American Heart Association meeting on Vascular Biology, and the Keystone Symposia.
Dr. Schmidt is known for innovative studies in the fields of diabetic complications (targeting RAGE), Alzheimer's disease, and, more recently, inflammation and tumor biology relevant to RAGE. Dr. Schmidt's research has utilized the tools of basic science to address issues relevant to important clinical problems in vascular diseases, particularly diabetes. Dr. Schmidt has been the recipient of an award in research at Columbia University, a fellowship from the Juvenile Diabetes Research Foundation, and a Clinician-Scientist award from the National Institutes of Aging. She is, at present, an Established Investigator of the American Heart Association. She is currently Co-principal Investigator on two Program Project Grants, in addition to several other peer-reviewed grants. Her publications include over 38 peer-reviewed papers and over 12 review/book chapters.
Dr. George D. Demetri is Associate Professor of Medicine at Harvard Medical School and Director of the Center for Sarcoma and Bone Oncology in the Department of Medical Oncology at the Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts. Dr. Demetri received his undergraduate degree in Biochemistry from Harvard College and medical degree from Stanford University School of Medicine in 1983, then went on to Internal Medicine residency and chief residency at the University of Washington Hospitals in Seattle. He then completed a fellowship in Medical Oncology at the Dana-Farber Cancer Institute and Harvard Medical School, where he has served as an Attending Physician since 1989. He is also an affiliate investigator with the Ludwig Institute for Cancer Research.
Dr. Demetri's research and clinical interests have focused on the translation of scientific discoveries into targeted drugs for the management of sarcomas as a model for solid tumor research and development. This work has led to the development of the oral drug Gleevec as an effective treatment for the gastrointestinal sarcoma known as GIST, and is continuing with the research leading to the new multi-targeted agent SU11248 for GIST resistant to Gleevec.
A fellow of the American College of Physicians, Dr. Demetri is a member of many professional societies and editorial boards of scientific journals. He is a member of the Board of Directors of the Connective Tissue Oncology Society, the chair of the Medical Advisory Board of the Sarcoma Alliance, and a member of the Medical Advisory Board of the Sarcoma Foundation of America. He has been instrumental in raising awareness of issues relating to sarcoma research and care by his activities on the Internet, and he founded a non-profit educational site for sarcoma patients and their families, www.sarcoma.net.
Dr. Mylari obtained his Ph.D in organic chemistry from Indiana University in 1966. After a year of post-doctoral research, he joined Pfizer in 1967. Over the next 34 years of continuous service at Pfizer, Dr. Mylari worked on a number of successful projects spanning both animal health and human health targets. These targets included projects in synthetic antibacterials, synthetic antiprotozoals, fermentation-derived antibacterials, semi-synthetic antimirobials, anti-inflammatory/analgesic agents, antihypertnsives, and therapeutic agents for diabetic complications. Dr. Mylari played a critical role in the successful commercialization of the animal health antibiotic, salinomycin, and discovery/development efforts leading to one of the potent aldose reductase inhibitors, zopolrestat (Phase III), for diabetic complications. Developing and executing effective strategies for protection of intellectual property was a hallmark of his career at Pfizer. He is experienced in almost all facets of drug discovery and development. Dr. Mylari has published extensively in major journals (62 publications, including journal publications and presentations). In addition, he is an inventor/co-inventor on 51 US patents with more US patents still pending.
Dr. Mylari retired from Pfizer in January 2001; and is now an independent R&D consultant with several clients, including Pfizer Inc. He is a member of the scientific advisory board of Millennium Pharmaceuticals.
|
